Skip to main content
. 2021 May 7;12:680068. doi: 10.3389/fimmu.2021.680068

Figure 3.

Figure 3

Pharmaceutical inhibition of PKM2 inhibits TLRs-induced activations of BMDMs, BMDCs and murine splenic B cells. BMDMs, BMDCs and murine splenic B cells were pretreated with PKM2 inhibitor PKM2-IN (2.5, 5 and 10 μM) for 2 hours followed by stimulations of LPS (100 ng/mL), R848 (1 μg/mL) and CpG-1826 (1 μM). FACS analysis of CD86 and CD40 expressions on BMDMs (A), BMDCs (B) and murine splenic B cells (C) at 24 hours. ELISA analysis of the levels of IL-12 and TNF-α secreted by BMDMs (D) and BMDCs (E) at 24 hours. Q-PCR analysis of the mRNA levels of IL-6 and TNF-α on murine splenic B cells at 6 hours. The data shown represent the means of three independent experiments and the error bars represent the S.E.M. *p < 0.05, **p < 0.01, ***p < 0.001, as determined by ANOVA tests.